» Articles » PMID: 37072441

Molecular Phenotypes of Mitochondrial Dysfunction in Clinically Non-manifesting Heterozygous PRKN Variant Carriers

Abstract

Homozygous or compound heterozygous (biallelic) variants in PRKN are causal for PD with highly penetrant symptom expression, while the much more common heterozygous variants may predispose to PD with highly reduced penetrance, through altered mitochondrial function. In the presence of pathogenic heterozygous variants, it is therefore important to test for mitochondrial alteration in cells derived from variant carriers to establish potential presymptomatic molecular markers. We generated lymphoblasts (LCLs) and human induced pluripotent stem cell (hiPSC)-derived neurons from non-manifesting heterozygous PRKN variant carriers and tested them for mitochondrial functionality. In LCLs, we detected hyperactive mitochondrial respiration, and, although milder compared to a biallelic PRKN-PD patient, hiPSC-derived neurons of non-manifesting heterozygous variant carriers also displayed several phenotypes of altered mitochondrial function. Overall, we identified molecular phenotypes that might be used to monitor heterozygous PRKN variant carriers during the prodromal phase. Such markers might also be useful to identify individuals at greater risk of eventual disease development and for testing potential mitochondrial function-based neuroprotective therapies before neurodegeneration advances.

Citing Articles

Non-Categorical Analyses Identify Rotenone-Induced 'Parkinsonian' Rats Benefiting from Nano-Emulsified Punicic Acid (Nano-PSO) in a Phenotypically Diverse Population: Implications for Translational Neurodegenerative Therapies.

Sanchez-Camacho J, Gomez-Chavarin M, Galindo-Solano N, Padilla-Cortes P, Maldonado-Garcia J, Perez-Sanchez G Int J Mol Sci. 2024; 25(23).

PMID: 39684350 PMC: 11640963. DOI: 10.3390/ijms252312635.


Histone post-translational modification and heterochromatin alterations in neurodegeneration: revealing novel disease pathways and potential therapeutics.

Fisher R, Torrente M Front Mol Neurosci. 2024; 17:1456052.

PMID: 39346681 PMC: 11427407. DOI: 10.3389/fnmol.2024.1456052.


Pathogenesis of Parkinson's disease: from hints from monogenic familial PD to biomarkers.

Hattori N, Funayama M, Imai Y, Hatano T J Neural Transm (Vienna). 2024; 131(6):709-719.

PMID: 38478097 DOI: 10.1007/s00702-024-02747-5.


GiOPARK Project: The Genetic Study of Parkinson's Disease in the Croatian Population.

Racki V, Bergant G, Papic E, Kovanda A, Hero M, Rozmaric G Genes (Basel). 2024; 15(2).

PMID: 38397244 PMC: 10888376. DOI: 10.3390/genes15020255.


Intracellular delivery of Parkin-RING0-based fragments corrects Parkin-induced mitochondrial dysfunction through interaction with SLP-2.

Zanon A, Guida M, Lavdas A, Corti C, Castelo Rueda M, Negro A J Transl Med. 2024; 22(1):59.

PMID: 38229174 PMC: 10790385. DOI: 10.1186/s12967-024-04850-3.


References
1.
Prasuhn J, Bruggemann N, Hessler N, Berg D, Gasser T, Brockmann K . An omics-based strategy using coenzyme Q10 in patients with Parkinson's disease: concept evaluation in a double-blind randomized placebo-controlled parallel group trial. Neurol Res Pract. 2020; 1:31. PMC: 7650116. DOI: 10.1186/s42466-019-0033-1. View

2.
Fazzini F, Lamina C, Raftopoulou A, Koller A, Fuchsberger C, Pattaro C . Association of mitochondrial DNA copy number with metabolic syndrome and type 2 diabetes in 14 176 individuals. J Intern Med. 2021; 290(1):190-202. PMC: 8359248. DOI: 10.1111/joim.13242. View

3.
Pacelli C, De Rasmo D, Signorile A, Grattagliano I, Di Tullio G, DOrazio A . Mitochondrial defect and PGC-1α dysfunction in parkin-associated familial Parkinson's disease. Biochim Biophys Acta. 2011; 1812(8):1041-53. DOI: 10.1016/j.bbadis.2010.12.022. View

4.
Schwartzentruber A, Boschian C, Lopes F, Myszczynska M, New E, Beyrath J . Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons. Sci Rep. 2020; 10(1):15485. PMC: 7511396. DOI: 10.1038/s41598-020-72345-4. View

5.
Konstantin Nissen S, Shrivastava K, Schulte C, Otzen D, Goldeck D, Berg D . Alterations in Blood Monocyte Functions in Parkinson's Disease. Mov Disord. 2019; 34(11):1711-1721. DOI: 10.1002/mds.27815. View